Neumora Therapeutics, Inc. Research And Development Expense

Quick Answer

Neumora Therapeutics, Inc. reported Research And Development Expense of $176.07 million for the year ending 2025.

  • Neumora Therapeutics, Inc. showed a decrease of -12.4% in Research And Development Expense from 2024 to 2025.
  • This data is from Neumora Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
  • XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 4 years of available data (2022 to 2025), Neumora Therapeutics, Inc.'s Research And Development Expense has grown by 91.9%.
  • Historical annual values: Fiscal year 2025: $176.07 million | Fiscal year 2024: $200.93 million | Fiscal year 2023: $142.72 million | Fiscal year 2022: $91.75 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: